- Home
- PRPO
PRPO
Precipio Inc.
as 11-15-2024 11:38am EST
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | OMAHA |
| Market Cap: | 9.5M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 7.5K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.07 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.31 - $8.49 | Next Earning Date: | 11-06-2024 |
| Revenue: | $17,411,000 | Revenue Growth: | 31.31% |
| Revenue Growth (this year): | 75.18% | Revenue Growth (next year): | N/A |
Latest Precipio Inc. News
PRPO Breaking Stock News: Dive into PRPO Ticker-Specific Updates for Smart Investing
Simply Wall St.
6 days ago
Precipio Third Quarter 2024 Earnings: US$0.42 loss per share (vs US$1.04 loss in 3Q 2023)
GlobeNewswire
9 days ago
Precipio Announces Q3-2024 Shareholder Update Call
GlobeNewswire
a month ago
Precipio Expands Bloodhound™ MPN Panel by Adding CALR Mutation Subtyping
GlobeNewswire
2 months ago
Precipio Announces Employee Stock Option Plan Repricing
Zacks
2 months ago
Zacks Initiates Coverage of Precipio With Outperform Recommendation
GlobeNewswire
3 months ago
Precipio Announces Q2-2024 Shareholder Update Call
GlobeNewswire
4 months ago
Precipio Reports $0.3M cash generated by operations (unaudited) in Q2-2024, as the company advances towards breakeven
GlobeNewswire
4 months ago
Precipio Reports $4.4M for Q2-2024 (unaudited) Revenues, a leap of 30% from Q1-2024
Compare PRPO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PRPO Precipio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.